Phase II Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients with Advanced Pancreatic Cancer

REFERENCES

• Saif, M.W. Is there a standard of care for the management of advanced pancreatic cancer? Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25–27, 2008. JOP. J Pancreas (Online) 2008, 9, 91–98.
   PubMedGoogle Scholar
• Burris, H.A.III; Moore, M.J.; Andersen, J.; Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15, 2403–2413.
   PubMed Web of Science ®Google Scholar
• Saif, M.W. Pancreatic cancer: is this bleak landscape finally changing? Highlights from the ‘43rd ASCO Annual Meeting’. Chicago, IL, USA. June 1–5, 2007. JOP 2007, 8(4), 365–373.
   PubMedGoogle Scholar
• Strimpakos, A.; Saif, M.W.; Syrigos, K.N. Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer Metastasis Rev. 2008, 27(3), 495–522.
   PubMed Web of Science ®Google Scholar
• Moore, M.J.; Goldstein, D.; Hamm, J.; Figer, A.; Hecht, J.R.; Gallinger, S.; Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25, 1960–1966.
   PubMed Web of Science ®Google Scholar
• Bissery, M.C.; Guenard, D.; Gueritte-Vogelein, F.; Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 1991, 51, 1845–1851.
   Google Scholar
• Schultz, R.M.; Merriman, R.L.; Toth, J.E.; Evaluation of new anticancer agents against the MIA PaCa and PANC-1 human pancreatic carcinoma xenografts. Oncol Res 1993, 5, 223–228.
   PubMed Web of Science ®Google Scholar
• Rougier, P.; Adenis, A.; Ducreus, M.; A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur. J. Cancer 2000, 36, 1016–1025.
   PubMed Web of Science ®Google Scholar
• Androulakis, N.; Kourousis, C.; Dimopoulos, M.A.; Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study. J Clin Oncol 1999, 17, 1779–1785.
   PubMed Web of Science ®Google Scholar
• Okada, S.; Sakata, Y.; Matsuno, S.; Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Br J Cancer 1999, 80, 438–443.
   PubMed Web of Science ®Google Scholar
• Gebbia, N.; Gebbia, V. Single agent paclitaxel in the treatment of unresectable and/or metastatic pancreatic adenocarcinoma. Eur. J. Cancer 1996, 32A, 1822–1823.
   PubMed Web of Science ®Google Scholar
• Whitehead, R.P.; Jacobson, J.; Brown, T.D.; Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic adenocarcinoma: a Southwest Oncology Group study. J Clin Oncol 1997, 15, 2414–2419.
   PubMed Web of Science ®Google Scholar
• Oettle, H.; Arnold, D.; Esser, M.; Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 2000, 11, 635–638. .
   PubMed Web of Science ®Google Scholar
• Mathew, A.E.; Mejillano, M.; Nath, J.P.; Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity. J Med Chem 1992, 35, 145–151.
   PubMed Web of Science ®Google Scholar
• Rowinsky, E.K.; Cazenave, L.A.; Donehower, RC Taxol – a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990, 82, 1247–1259.
   PubMed Web of Science ®Google Scholar
• Kintzel, P.E. Prophylaxis for paclitaxel hypersensitivity reactions. Ann Pharmacother 2001, 35, 1114–1117.
   PubMed Web of Science ®Google Scholar
• Kloover, J.S.; den Bakker, M.A.; Gelderblom, H.; Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br. J. Cancer 2004, 90, 304–305.
   PubMed Web of Science ®Google Scholar
• Mielke, S.; Sparreboom, A.; Mross, K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer 2006, 42, 24–30.
   PubMed Web of Science ®Google Scholar
• Ganning, A.E.; Brunk, U.; Dallner, G. Phthalate esters and their effect on the liver. Hepatology 1984, 4, 541–547.
   PubMed Web of Science ®Google Scholar
• Hill, S.S.; Shaw, B.R.; Wu, A.H. The clinical effects of plasticizers, antioxidants, and other contaminants in medical polyvinylchloride tubing during respiratory and non-respiratory exposure. Clin Chim Acta 2001, 304, 1–8.
   PubMed Web of Science ®Google Scholar
• Kim, S.C.; Kim, D.W.; Shim, Y.H.; In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Controlled Release 2001, 72, 191–202.
   PubMed Web of Science ®Google Scholar
• Kim, T.Y.; Kim, D.W.; Chung, J.Y.; Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 2004, 10, 3708–3716.
   PubMed Web of Science ®Google Scholar
• Therasse, P.; Arbuck, S.G.; Eisenhauer, E.A.; New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92, 205–216.
   PubMed Web of Science ®Google Scholar
• NCI Common Terminology Criteria for Adverse Events. V.3.0 (NCI CTC). http://ctep.cancer.gov/reporting/ctc_v30.html
   Google Scholar
• Cohen, S.J.; Ho, L.; Ranganathan, S.; Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol 2003, 21, 1301–1306.
   PubMed Web of Science ®Google Scholar
• Southwest Oncology Group (SWOG), A National Clinical Research Group; http://www.swogstat.org/stat/public/one_nonparametric_survival.htm
   Google Scholar
• Kaplan, E.L.; Meier, P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53, 457–481.
   Web of Science ®Google Scholar
• Gelderblom, H.; Verweij, J.; Nooter, K.; Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 2001, 37, 1590–1598.
   PubMed Web of Science ®Google Scholar
• Sparreboom, A.; van Tellingen, O.; Nooijen, W.J.; Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle. Cremophor. E. L. Cancer Res 1996, 56, 2112–2115.
   PubMed Web of Science ®Google Scholar
• Nuijen, B.; Bouma, M.; Schellens, J.H.; Progress in the development of alternative pharmaceutical formulations of taxanes. Invest New Drugs 2001, 19, 143–153.
   PubMed Web of Science ®Google Scholar
• Maeda, H.; Wu, J.; Sawa, T.; Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65, 271–284.
   PubMed Web of Science ®Google Scholar
• Catalano, G. A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann Oncol 1999, 10(11), 1377–1379.
   PubMed Web of Science ®Google Scholar
• Lenzi, R.; Yalcin, S.; Evans, D.B.; Abbruzzese, J.L. Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy. Cancer Invest 2002, 20(4), 464–472.
   PubMed Web of Science ®Google Scholar
• Kulke, M.H.; Niedzwiecki, D.; Tempero, M.A.; Hollis, D.R.; Mayer, R.J. A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabine/irinotecan in patients with metastatic pancreatic cancer (CALGB 89904). Proc Am Soc Clin Oncol 2004, 23, 315 Abstract 4011.
   Google Scholar